

# Scott Kopetz

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2225634/scott-kopetz-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

525 papers	28,226 citations	81 h-index	157 g-index
650 ext. papers	35,348 ext. citations	5.5 avg, IF	7.02 L-index

#	Paper	IF	Citations
525	Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective.. <i>Cancer and Metastasis Reviews</i> , <b>2022</b> , 41, 147	9.6	2
524	Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. <b>2022</b> , 10,		2
523	Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.. <i>Scientific Reports</i> , <b>2022</b> , 12, 1248	4.9	0
522	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS233-TPS233 <sup>0</sup>	2.2	0
521	The immune impact of PI3K-AKT pathway inhibition in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 154-154	2.2	
520	NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) studyA randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer	2.2	0
519	Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis.. <i>Oncologist</i> , <b>2022</b> , 27, 371-379	5.7	0
518	Clinical and pathologic features correlated with rare favorable survival in patients with mutated colorectal cancer.. <i>Journal of Gastrointestinal Oncology</i> , <b>2022</b> , 13, 647-656	2.8	
517	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100181	3.6	2
516	Patient-derived micro-organospheres enable clinical precision oncology.. <i>Cell Stem Cell</i> , <b>2022</b> ,	18	5
515	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2213588	10.4	2
514	Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. <i>ESMO Open</i> , <b>2022</b> , 7, 100477	6	1
513	Sotorasib for previously treated colorectal cancers with KRAS mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.. <i>Lancet Oncology, The</i> , <b>2021</b> ,	21.7	18
512	A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. <i>Statistics in Medicine</i> , <b>2021</b> , 41, 374	2.3	0
511	An analysis of research biopsy core variability from over 5000 prospectively collected core samples. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 94	9.8	0
510	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2021</b> , 20, 137-147.e1	3.8	3
509	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3039-3049	12.9	3

508	Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status. <i>British Journal of Surgery</i> , <b>2021</b> , 108, 968-975	5.3	10
507	Comprehensive Clinical and Molecular Characterization of -Mutant Colorectal Cancer. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	7
506	Phase II/III study of Circulating tumor DNA as a predictive Biomarker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS3622-TPS3622	2.2	0
505	Serial circulating tumor DNA (ctDNA) monitoring in metastatic colorectal cancer (mCRC) reveals dynamic profile of actionable alterations.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3572-3572	2.2	0
504	A novel clinical tool to estimate risk of false negative KRAS mutation in circulating tumor DNA testing.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3594-3594	2.2	
503	Clinical and Functional Characterization of Atypical / Mutations in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4587-4598	12.9	4
502	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2738-2747	24.4	11
501	Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 208-211	9.7	17
500	Expanded Low Allele Frequency and V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 52-59	12.9	6
499	Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , <b>2021</b> , 25, 186-194	3.3	10
498	Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies. <i>Oncologist</i> , <b>2021</b> , 26, 107-114	5.7	5
497	Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 120-130	12.9	11
496	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS148-TPS148 <sup>2</sup>	2.2	0
495	Global BRAF testing practices in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 128-128	2.2	0
494	Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 110-110	2.2	
493	PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS143-TPS143	2.2	0
492	Utility of circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 119-119	2.2	1
491	NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) StudyA randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS158-TPS158	2.2	1

490	Real-world genomic and treatment landscape in advanced colorectal cancer identifies treatment differences pre- and post-ctDNA genomic profiling.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 39-39	2.2	
489	An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS157-TPS157	2.2	1
488	Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 79-79	2.2	3
487	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 273-284	2.2	60
486	Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 285-294	2.2	53
485	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. <i>Gastroenterology</i> , <b>2021</b> , 161, 196-210	13.3	5
484	The Provocative Roles of Platelets in Liver Disease and Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 643815	5.3	1
483	SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. <i>Annals of Oncology</i> , <b>2021</b> , 32, S213-S214	10.3	3
482	Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5449-5451	12.9	3
481	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , <b>2021</b> , 12, 5086	17.4	6
480	Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer. <i>Journal of the American College of Surgeons</i> , <b>2021</b> , 233, 272-284.e13	14.1	3
479	Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 Axis. <i>Advanced Science</i> , <b>2021</b> , 8, e2004673	13.6	3
478	BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. <i>BMJ Open</i> , <b>2021</b> , 11, e047831	3	2
477	Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
476	Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , <b>2021</b> , 1	3.3	7
475	ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1663-1670	12.9	14
474	Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1681-1694	12.9	5
473	Liquid biopsies for residual disease and recurrence.. <i>Med</i> , <b>2021</b> , 2, 1292-1313	31.7	1

472	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.. <i>ESMO Open</i> , <b>2021</b> , 6, 100328	6	2
471	The emergence of targetable pathways in colorectal cancer.. <i>Clinical Advances in Hematology and Oncology</i> , <b>2021</b> , 19, 774-783	0.6	2
470	Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 346	9.8	32
469	Population-based Screening for in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4599-4605	12.9	12
468	Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract. <i>Genes</i> , <b>2020</b> , 11,	4.2	39
467	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 248-255.e6	3.8	2
466	Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. <i>European Radiology</i> , <b>2020</b> , 30, 4496-4503	8	3
465	Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 229-234	5.7	5
464	LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC. <i>Annals of Oncology</i> , <b>2020</b> , 31, S243	10.3	2
463	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , <b>2020</b> , 17, 757-770	19.4	82
462	Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. <i>Gut</i> , <b>2020</b> , 69, 748-763	19.2	74
461	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. <i>Cancer Cell</i> , <b>2020</b> , 37, 371-386.e12	24.3	28
460	Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 132-136.e3	3.8	1
459	Colon Cancer in Patients Under 25 Years Old: A Different Disease?. <i>Journal of the American College of Surgeons</i> , <b>2020</b> , 230, 648-656	4.4	8
458	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , <b>2020</b> , 10, 3080	4.9	3
457	Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, 383-388	2.3	18
456	Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3625-3625	2.2	2
455	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4001-4001	2.2	22

454	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. <i>Oncotarget</i> , <b>2020</b> , 11, 600-618	3.3	9
453	A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 1500-1508	7.3	20
452	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 48-56.e2	3.8	1
451	Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2020</b> , 47, 5-18	2.7	0
450	International Harmonization of Provisional Diagnostic Criteria for -Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel.. <i>JCO Precision Oncology</i> , <b>2020</b> , 4, 6-19	3.6	11
449	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. <i>Nature Medicine</i> , <b>2020</b> , 26, 39-46	50.5	119
448	Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. <i>Nature Communications</i> , <b>2020</b> , 11, 5332	17.4	5
447	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. <i>Gastroenterology</i> , <b>2020</b> , 159, 2146-2162.e33	13.3	34
446	Reply to S. Boutayeb et al. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, 525	2.3	1
445	455P A meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing. <i>Annals of Oncology</i> , <b>2020</b> , 31, S435	10.3	2
444	Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer. <i>Targeted Oncology</i> , <b>2020</b> , 15, 567-577	5	5
443	Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. <i>BMC Cancer</i> , <b>2020</b> , 20, 871	4.8	4
442	APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases. <i>Annals of Surgery</i> , <b>2020</b> , 272, 1080-1085	7.8	20
441	AMPK $\beta$ 1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. <i>Oncogene</i> , <b>2020</b> , 39, 637-650	9.2	8
440	Biomarker-guided therapy for colorectal cancer: strength in complexity. <i>Nature Reviews Clinical Oncology</i> , <b>2020</b> , 17, 11-32	19.4	103
439	Development and Application of Duplex Sequencing Strategy for Cell-Free DNA-Based Longitudinal Monitoring of Stage IV Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , <b>2019</b> , 21, 994-1009	5.1	3
438	Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. <i>Cancers</i> , <b>2019</b> , 11,	6.6	20
437	Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1632-1643	59.2	481



436	Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	5
435	Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. <i>Angewandte Chemie</i> , <b>2019</b> , 131, 4223-4227	3.6	
434	Back to the Colorectal Cancer Consensus Molecular Subtype Future. <i>Current Gastroenterology Reports</i> , <b>2019</b> , 21, 5	5	28
433	Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. <i>Angewandte Chemie - International Edition</i> , <b>2019</b> , 58, 4179-4183	16.4	6
432	Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA. <i>Cancer Genetics</i> , <b>2019</b> , 237, 82-89	2.3	5
431	Mutation Status of , and is Superior to Mutation Status of Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5843-5851	12.9	69
430	Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1101-1103	13.4	0
429	Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation. <i>Journal of the American College of Surgeons</i> , <b>2019</b> , 229, 286-294.e1	4.4	36
428	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. <i>Cancer Cell</i> , <b>2019</b> , 35, 559-572.e7	24.3	187
427	Clinical and molecular characterization of early-onset colorectal cancer. <i>Cancer</i> , <b>2019</b> , 125, 2002-2010	6.4	110
426	Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials. <i>Journal of Surgical Oncology</i> , <b>2019</b> , 119, 642-652	2.8	19
425	Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	6
424	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1460-1469	2.2	114
423	Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. <i>Modern Pathology</i> , <b>2019</b> , 32, 1053-1064	9.8	27
422	Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts <b>2019</b> , 7, 37		77
421	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 505-510	8.7	14
420	Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. <i>JAMA Oncology</i> , <b>2019</b> , 5, e191870	13.4	126
419	How liquid biopsies can change clinical practice in oncology. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1580-1590	10.3	107

418	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 7035-7045	12.9	72
417	CTC analysis: an update on technological progress. <i>Translational Research</i> , <b>2019</b> , 212, 14-25	11	10
416	Genetic profiling as a clinical tool in advanced parathyroid carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 1977-1986	4.9	12
415	Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919864850	5.4	6
414	Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6899-6908	12.9	42
413	Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 964	4.8	8
412	Targeting () Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	7
411	Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3604-3604	2.2	4
410	Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 537-537	2.2	2
409	Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 596-596	2.2	5
408	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 635-635	2.2	22
407	Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 688-688	2.2	12
406	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC).. <i>Journal of</i>	2.2	3
405	Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. <i>Oncotarget</i> , <b>2019</b> , 10, 4703-4718	3.3	6
404	Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 604-604	2.2	
403	Systematic review of three decades of clinical trials in metastatic colorectal cancer: Making lemonade out of lemons?. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 656-656	2.2	
402	Population pharmacokinetics (popPK) of Sym004 to evaluate the effect of intrinsic and extrinsic factors on exposure in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 496-496	2.2	22
401	Quantifying the evolution of tumor architecture using serial circulating tumor DNA.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 600-600	2.2	



400	Prediction model for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3590-3590	2.2	
399	Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3579-3579	2.2	2
398	The association between female hormonal supplementation and molecular types in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15133-e15133	2.2	
397	Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15046-e15046	2.2	
396	A systematic review of surrogate endpoints (SEPs) for overall survival (OS) in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e18206-e18206	2.2	0
395	FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15060-e15060	2.2	
394	Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3587-3587	2.2	
393	Reporting of patient (pt) characteristics (c) and use of stratification factors (SF) in phase III trials for metastatic colorectal cancer (mCRC): Urgent need for standardization.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15055-e15055	2.2	
392	Meat consumption and BRAF mutation status in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15135-e15135	2.2	
391	Association between gene fusions and anti-EGFR resistance signature in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3564-3564	2.2	
390	A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. <i>DMM Disease Models and Mechanisms</i> , <b>2019</b> , 12,	4.1	7
389	Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. <i>Oncologist</i> , <b>2019</b> , 24, e671-e676	5.7	1
388	Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	5
387	Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	4
386	Validation of Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer.. <i>JCO Precision Oncology</i> , <b>2019</b> , 3, 1-13	3.6	14
385	The BE GONE trial study protocol: a randomized crossover dietary intervention of dry beans targeting the gut microbiome of overweight and obese patients with a history of colorectal polyps or cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 1233	4.8	4
384	Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2019</b> , 38, 492	12.8	14
383	Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases. <i>Surgery</i> , <b>2019</b> , 165, 329-336	3.6	16

382	New therapies and insights into the changing landscape of colorectal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2019</b> , 16, 79-80	24.2	19
381	Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. <i>Annals of Oncology</i> , <b>2019</b> , 30, 243-249	10.3	105
380	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 340-345	8.7	17
379	DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 641-651	12.9	14
378	Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. <i>Annals of Surgery</i> , <b>2019</b> , 269, 917-923	7.8	78
377	Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 76-86	4.3	
376	Impact of Prior Hepatectomy History on Local Tumor Progression after Percutaneous Ablation of Colorectal Liver Metastases. <i>Journal of Vascular and Interventional Radiology</i> , <b>2018</b> , 29, 395-403.e1	2.4	12
375	Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3867-3877	12.9	28
374	Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. <i>Future Oncology</i> , <b>2018</b> , 14, 1869-1874	3.6	22
373	Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , <b>2018</b> , 19, 11	5.4	3
372	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <i>Journal of Immunotherapy</i> , <b>2018</b> , 41, 284-291	5	8
371	Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1085-1092	13.4	40
370	Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases. <i>British Journal of Surgery</i> , <b>2018</b> , 105, 1200-1209	5.3	10
369	Biomarkers in colorectal liver metastases. <i>British Journal of Surgery</i> , <b>2018</b> , 105, 618-627	5.3	37
368	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, e175245	13.4	54
367	The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 888-894	9.7	15
366	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Annals of Oncology</i> , <b>2018</b> , 29, 44-70	10.3	260
365	Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 139-144	10.3	17

364	Untying the gordian knot of targeting MET in cancer. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 66, 95-103	14.4	14
363	Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 1409-1417	9.7	28
362	SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 684-692	3.6	45
361	The somatic mutation landscape of premalignant colorectal adenoma. <i>Gut</i> , <b>2018</b> , 67, 1299-1305	19.2	33
360	Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. <i>Annals of Surgery</i> , <b>2018</b> , 267, 514-520	7.8	46
359	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 181-188	12.9	89
358	Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. <i>Gut</i> , <b>2018</b> , 67, 1095-1102	19.2	16
357	Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 179-187	3.1	17
356	First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors. <i>Cancer</i> , <b>2018</b> , 124, 315-324	6.4	21
355	BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, v109	10.3	8
354	Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis. <i>Translational Oncology</i> , <b>2018</b> , 11, 1188-1201	4.9	35
353	Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 107	5.3	15
352	Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e699-e709	3.8	21
351	Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. <i>Annals of Oncology</i> , <b>2018</b> , 29, 2061-2067	10.3	23
350	Bioactive lipid metabolism in platelet "first responder" and cancer biology. <i>Cancer and Metastasis Reviews</i> , <b>2018</b> , 37, 439-454	9.6	13
349	Abstract 2603: Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab + ipilimumab in CheckMate-142 <b>2018</b> ,		4
348	Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3507-3507	2.2	4
347	Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3511-3511	2.2	7

346	Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3513-3513	2.2	7
345	Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3533-3533	2.2	2
344	Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3549-3549	2.2	1
343	International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3594-3594	2.2	4
342	The characteristics of ARID1A mutations in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3595-3595	2.2	3
341	Circulating tumor DNA profiling to identify patients with metastatic colorectal cancer with improved overall survival following Sym004 treatment.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e15577-e15577	2.2	1
340	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS3613-TPS3613	2.2	6
339	A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS3620-TPS3620	2.2	6
338	Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 554-554	2.2	18
337	Impact of microsatellite instability (MSI) on tumor clonal evolution in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 616-616	2.2	1
336	BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 627-627	2.2	28
335	Serial monitoring of ctDNA to highlight mutation profiles in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 641-641	2.2	1
334	Association of phosphatidylinositol 3-kinase (PI3K) pathway activation with increased immune checkpoint expression in colorectal cancer (CRC) patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 653-653	2.2	2
333	Detection and description of ERBB2 amplification using circulating cell free tumor DNA (ctDNA) genomic analysis in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 661-661	2.2	2
332	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- $\beta$ in patients with heavily pretreated CRC: Preliminary results from a phase I trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 764-764	2.2	10
331	Preclinical development of tumor-infiltrating lymphocyte therapy for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 95-95	2.2	1
330	Clinical and molecular characterization of early-onset colorectal cancer patients with inflammatory bowel disease.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 689-689	2.2	
329	Association of SMAD4 gene mutation with incidence of peritoneal involvement in unresectable metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 772-772	2.2	

328	Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 619-619	2.2	
327	Predictors for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 634-634	2.2	
326	Malignant peritoneal mesothelioma: Clinicopathological features, prognostic factors, and survival outcomes.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 650-650	2.2	
325	Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS870-TPS870	2.2	0
324	Consensus molecular subtypes (CMS), markers of systemic inflammation (SI) and clinicopathological parameters in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e15600-e15600	2.2	
323	A priori filtering of post-operative (post-op) circulating tumor DNA (ctDNA) to predict recurrence in post-metastasectomy colorectal cancer patients (CRC pts) without knowledge of tumor genotype.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12044-12044	2.2	1
322	Refining the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e15686-e15686	2.2	
321	Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3522-3522	2.2	0
320	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1062-1072	12.9	143
319	Integrated safety summary for trifluridine/tipiracil (TAS-102). <i>Anti-Cancer Drugs</i> , <b>2018</b> , 29, 89-96	2.4	8
318	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. <i>Cancer Discovery</i> , <b>2018</b> , 8, 164-174	12.4	148
317	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 773-779	2.2	938
316	Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2018789032	2.2	25
315	TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/β-catenin signalling. <i>Nature Cell Biology</i> , <b>2018</b> , 20, 1421-1433	23.4	42
314	Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. <i>Oncotarget</i> , <b>2018</b> , 9, 10259-10271	3.3	22
313	RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 2457-2466	3.1	15
312	Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 895-902	4.3	
311	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , <b>2018</b> , 100, 35-45	7.5	20



310	RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , <b>2017</b> , 21, 68-77	3.3	25
309	Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2017</b> , 40, 277-282	2.7	12
308	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3657-3666	12.9	44
307	Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 122, 146-151	5.3	32
306	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1453-1486	2.2	191
305	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4146-4154	12.9	29
304	Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. <i>British Journal of Surgery</i> , <b>2017</b> , 104, 760-768	5.3	68
303	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2017</b> , 141, 625-657	5	54
302	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. <i>Journal of Molecular Diagnostics</i> , <b>2017</b> , 19, 187-225	5.1	76
301	Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , <b>2017</b> , 43, 1040-1049	3.6	15
300	Tumor Angiogenesis <b>2017</b> , 1-32		
299	Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4578-4591	12.9	58
298	Modeling of Patient-Derived Xenografts in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 1435-1442	6.1	23
297	Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. <i>Advances in Radiation Oncology</i> , <b>2017</b> , 2, 455-464	3.3	13
296	Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. <i>Journal of Molecular Diagnostics</i> , <b>2017</b> , 19, 514-524	5.1	21
295	Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5246-5254	12.9	22
294	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. <i>Genome Biology</i> , <b>2017</b> , 18, 98	18.3	75
293	Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer. <i>Genome Research</i> , <b>2017</b> , 27, 1287-1299	9.7	127



292	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5648-5656	12.9	38
291	Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 411-419	7.3	161
290	Targeting -Mutant Colorectal Cancer: Progress in Combination Strategies. <i>Cancer Discovery</i> , <b>2017</b> , 7, 558-560	24.4	18
289	Molecular Biomarkers for the Evaluation of Colorectal Cancer. <i>American Journal of Clinical Pathology</i> , <b>2017</b> , 147, 221-260	1.9	19
288	Platelets: First Responders In Cancer Progression and Metastasis <b>2017</b> , 1111-1132		3
287	Oncogenic drives invasion and maintains metastases in colorectal cancer. <i>Genes and Development</i> , <b>2017</b> , 31, 370-382	12.6	80
286	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. <i>Nature Reviews Cancer</i> , <b>2017</b> , 17, 79-92	31.3	423
285	Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. <i>Annals of Oncology</i> , <b>2017</b> , 28, 468-477	10.3	41
284	Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. <i>Annals of Oncology</i> , <b>2017</b> , 28, 642-650	10.3	35
283	Planned Treatment of Advanced Metastatic Disease with Completion Ablation After Hepatic Resection. <i>Journal of Gastrointestinal Surgery</i> , <b>2017</b> , 21, 628-635	3.3	11
282	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , <b>2017</b> , 8, 1050	17.4	75
281	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183949	3.7	21
280	BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2624-2630	2.2	176
279	Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2631-2638	2.2	39
278	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. <i>Journal of Oncology Practice</i> , <b>2017</b> , 13, 333-337	3.1	20
277	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	19
276	Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. <i>Journal of Gastrointestinal Oncology</i> , <b>2017</b> , 8, 199-212	2.8	18
275	Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 3857-3864	3.1	10

274	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 4051-4058	3.1	19
273	Platelet "first responders" in wound response, cancer, and metastasis. <i>Cancer and Metastasis Reviews</i> , <b>2017</b> , 36, 199-213	9.6	98
272	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1182-1191	21.7	1317
271	Recent developments in the treatment of metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2017</b> , 9, 551-564	5.4	68
270	Global and targeted serum metabolic profiling of colorectal cancer progression. <i>Cancer</i> , <b>2017</b> , 123, 4066-4074	6.4	38
269	The potential role of platelets in the consensus molecular subtypes of colorectal cancer. <i>Cancer and Metastasis Reviews</i> , <b>2017</b> , 36, 273-288	9.6	26
268	Platelets, circulating tumor cells, and the circulome. <i>Cancer and Metastasis Reviews</i> , <b>2017</b> , 36, 235-248	9.6	43
267	Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. <i>Cancer</i> , <b>2017</b> , 123, 1011-1017	6.4	30
266	Predictors of health-related quality of life and association with survival may identify colorectal cancer patients at high risk of poor prognosis. <i>Quality of Life Research</i> , <b>2017</b> , 26, 319-330	3.7	15
265	Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. <i>Surgery</i> , <b>2017</b> , 161, 332-340	3.6	37
264	MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. <i>Journal of Pathology</i> , <b>2017</b> , 241, 67-79	9.4	8
263	Why a One Size Fits All Approach to Might Not Fit Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 545-547	7.3	3
262	Early-Onset Signet-Ring Cell Adenocarcinoma of the Colon: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , <b>2017</b> , 2017, 2832180	0.9	6
261	Metastasis regulation by PPARD expression in cancer cells. <i>JCI Insight</i> , <b>2017</b> , 2, e91419	9.9	38
260	Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1524-1524	2.2	1
259	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3505-3505	2.2	34
258	Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3522-3522	2.2	23
257	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3531-3531	2.2	24

256	Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3548-3548	2.2	4
255	Prognostic implications of TAMs in colorectal cancer hepatic metastases.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3574-3574	2.2	1
254	Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS mutations.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3589-3589	2.2	6
253	BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil (5-FU)/irinotecan (IRI)/CTP with or without 5-FU.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3625-3625	2.2	3
252	LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from colorectal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS3625-TPS3625	2.2	4
251	Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 519-519	2.2	42
250	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 520-520	2.2	85
249	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. <i>PLoS ONE</i> , <b>2017</b> , 12, e0173345	3.7	49
248	<i>Streptococcus gallolyticus</i> subsp. <i>gallolyticus</i> promotes colorectal tumor development. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006440	7.6	85
247	Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 28696-28710	3.3	12
246	A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. <i>Oncotarget</i> , <b>2017</b> , 8, 41806-41814	3.3	12
245	FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 39268-39279	3.3	39
244	Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. <i>Oncotarget</i> , <b>2017</b> , 8, 57882-57888	3.3	8
243	Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment. <i>American Journal of Cancer Research</i> , <b>2017</b> , 7, 2587-2599	4.4	2
242	Platelet microparticles: small payloads with profound effects on tumor growth. <i>Non-coding RNA Investigation</i> , <b>2017</b> , 1,	0.6	3
241	Arginine methylation of EGFR in circulating tumor cells: A new biomarker for predicting resistance to anti-EGFR agents.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3590-3590	2.2	
240	DNA sequencing of the small bowel adenocarcinomas to identify targetable ErbB2 mutations.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15800-e15800	2.2	
239	Molecular characterization of TP53 mutations and copy number change in colorectal cancers.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15143-e15143	2.2	

238	Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11551-11551	2.2	
237	Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11609-11609	2.2	
236	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. <i>Gut</i> , <b>2016</b> , 65, 977-989	19.2	99
235	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1352-1365	24.4	150
234	Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. <i>Scientific Reports</i> , <b>2016</b> , 6, 28910	4.9	116
233	BRAF-Directed Therapy in Metastatic Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , <b>2016</b> , 22, 175-82.	2.2	27
232	Impact of multimodal therapy in locally recurrent rectal cancer. <i>British Journal of Surgery</i> , <b>2016</b> , 103, 753-762	5.3	27
231	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1397-404	6.1	61
230	Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 1352-61	8.7	58
229	Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3989-91	12.9	8
228	Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 1378-84	3.6	7
227	Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer centre. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 103-9	8.7	25
226	High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. <i>Clinical Colorectal Cancer</i> , <b>2016</b> , 15, e1-7	3.8	32
225	Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. <i>Annals of Oncology</i> , <b>2016</b> , 27, 795-800	10.3	107
224	RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 2635-43	3.1	82
223	Abstract 8: Global and targeted metabolomic profiling of colorectal cancer progression <b>2016</b> ,		2
222	Nivolumab + ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3501-3501	2.2	70
221	Association of primary (1 <sup>st</sup> ) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (EGFR) therapy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3506-3506	2.2	13

220	HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3517-3517	2.2	48
219	Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3520-3520	2.2	2
218	A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3563-3563	2.2	6
217	Is the neutrophil-lymphocyte ratio (NLR) a predictive and prognostic factor in rectal cancer patients treated with neoadjuvant chemoradiation (nCRT)?.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3605-3605	2.2	2
216	Antibody-independent isolation and characterization of circulating tumor cells using dielectrophoresis: Fluid flow fractionation in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23023-e23023	2.2	1
215	Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 265-265	2.2	1
214	Examining plasma microRNA markers for colorectal cancer at different stages. <i>Oncotarget</i> , <b>2016</b> , 7, 11434-11434	3.3	63
213	Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. <i>Oncotarget</i> , <b>2016</b> , 7, 39595-39608	3.3	72
212	Phase II study of bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 144-144	2.2	
211	Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3607-3607	2.2	
210	Identification of novel EGFR ectodomain mutations based on a large database of clinical circulating cell-free DNA sequencing tests.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23167-e23167	2.2	
209	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. <i>Oncotarget</i> , <b>2016</b> , 7, 67495-67506	3.3	32
208	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. <i>Oncotarget</i> , <b>2016</b> , 7, 54627-54631	3.3	39
207	Molecular spectrum of , , , , and somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. <i>Journal of Gastrointestinal Oncology</i> , <b>2016</b> , 7, 882-902	2.8	29
206	Addition of RAS Mutation Status May Strengthen the Predictive Model for Progression of Indeterminate Pulmonary Nodules. <i>Annals of Surgery</i> , <b>2016</b> , 264, e7	7.8	
205	Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study. <i>Annals of Oncology</i> , <b>2016</b> , 27, vi158	10.3	7
204	Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1068-1074	10.3	26
203	Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases. <i>Journal of the American College of Surgeons</i> , <b>2016</b> , 223, 99-108	4.4	52



202	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. <i>Cancer</i> , <b>2016</b> , 122, 1836-43	6.4	25
201	A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 195-205	7.5	24
200	Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2644-51	12.9	63
199	Blood-based tests for colorectal cancer screening: do they threaten the survival of the FIT test?. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 664-71	4	34
198	Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 977-84	4.3	28
197	Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2015</b> , 14, 203-18	3.8	24
196	Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 653-9	14.4	41
195	A decision support framework for genomically informed investigational cancer therapy. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	135
194	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4023-31	2.2	315
193	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2753-62	2.2	295
192	The consensus molecular subtypes of colorectal cancer. <i>Nature Medicine</i> , <b>2015</b> , 21, 1350-6	50.5	2332
191	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4032-8	2.2	424
190	Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 899-906	12.9	158
189	Is complete liver resection without resection of synchronous lung metastases justified?. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 1585-92	3.1	52
188	Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 357-64	12.9	101
187	Topoisomerase II $\beta$ in chromosome instability and personalized cancer therapy. <i>Oncogene</i> , <b>2015</b> , 34, 4019-31	3.1	105
186	RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 834-842	3.1	79
185	Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. <i>British Journal of Surgery</i> , <b>2015</b> , 102, 1175-83	5.3	133



184 Targeted Therapy in Solid Tumors: Colorectal Cancer **2015**, 193-204

183	Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. <i>Cancer</i> , <b>2015</b> , 121, 2968-75	6.4	17
182	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , <b>2015</b> , 6, 12809-21	3.3	77
181	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140712	3.7	442
180	Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. <i>Oncologist</i> , <b>2015</b> , 20, 127-33	5.7	79
179	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. <i>Annals of Oncology</i> , <b>2015</b> , 26, 731-736	10.3	175
178	BRAF Mutations in Non-Metastatic Colorectal Cancer: Current Relevance and Future Implications. <i>Current Colorectal Cancer Reports</i> , <b>2015</b> , 11, 303-310	1	
177	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. <i>BMC Cancer</i> , <b>2015</b> , 15, 713	4.8	33
176	BRAF inhibitors: experience in thyroid cancer and general review of toxicity. <i>Hormones and Cancer</i> , <b>2015</b> , 6, 21-36	5	43
175	Association between KRAS mutation and lung metastasis in advanced colorectal cancer. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 424-8	8.7	61
174	Clinical actionability enhanced through deep targeted sequencing of solid tumors. <i>Clinical Chemistry</i> , <b>2015</b> , 61, 544-53	5.5	76
173	Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 1088-97	8.7	99
172	The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 539-46	8.7	28
171	Expanded RAS: refining the patient population. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 682-5	2.2	50
170	PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 4529-43	15.9	85
169	Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1510-1510	2.2	4
168	First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2564-2564	2.2	4
167	Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3511-3511	2.2	9

166	Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3608-3608	2.2	1
165	S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS790-TPS790 <sup>2</sup>	2.2	2
164	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , <b>2015</b> , 6, 26886-94	3.3	38
163	5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. <i>Oncotarget</i> , <b>2015</b> , 6, 41706-21	3.3	71
162	BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. <i>Journal of Gastrointestinal Oncology</i> , <b>2015</b> , 6, 660-7 <sup>2.8</sup>	2.8	88
161	Next-generation sequencing of advanced, relapsed colorectal adenocarcinoma (CRC) to reveal mutations affecting Wnt, MAPK and PI3K pathway signaling: Emergence of novel combinatorial strategies.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 605-605	2.2	
160	Multiple independent methods fail to confirm MET amplification rate reported in literature for metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 572-572	2.2	
159	Proteomic features of colorectal cancer independently predict relapse-free survival.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 616-616	2.2	
158	Acquired mutations in MAPK signaling pathway following initial pharmacological response in BRAF-mutated metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 629-629	2.2	
157	Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 580-580	2.2	
156	Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3612-3612	2.2	
155	A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e14700-e14700	2.2	
154	Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3601-3601	2.2	
153	Predictors of clonal evolution in metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3604-3604	2.2	
152	Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 11048-11048	2.2	1
151	Recurrent parathyroid carcinoma and the need for molecular profiling to aid in prognostication and therapeutics.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e17012-e17012	2.2	
150	Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5537-46	12.9	115
149	Platelets and cancer: a casual or causal relationship: revisited. <i>Cancer and Metastasis Reviews</i> , <b>2014</b> , 33, 231-69	9.6	195

148	Combined targeting of STAT3/NF- $\kappa$ B/COX-2/EP4 for effective management of pancreatic cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1259-73	12.9	63
147	Therapeutic silencing of KRAS using systemically delivered siRNAs. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 2876-85	6.1	59
146	Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). <i>Annals of Oncology</i> , <b>2014</b> , 25, 1032-8	10.3	174
145	Convergence of nanotechnology and cancer prevention: are we there yet?. <i>Cancer Prevention Research</i> , <b>2014</b> , 7, 973-92	3.2	9
144	Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. <i>Annals of Diagnostic Pathology</i> , <b>2014</b> , 18, 266-70	2.2	5
143	Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. <i>Journal of Pathology</i> , <b>2014</b> , 232, 199-209	9.4	882
142	FXR silencing in human colon cancer by DNA methylation and KRAS signaling. <i>American Journal of Physiology - Renal Physiology</i> , <b>2014</b> , 306, G48-58	5.1	49
141	Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2014</b> , 13, 164-71	3.8	77
140	Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 2008-2014	10.3	38
139	Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. <i>Cancer</i> , <b>2014</b> , 120, 1162-70	6.4	33
138	Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 3230-40	6.1	12
137	Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. <i>BMC Cancer</i> , <b>2014</b> , 14, 660	4.8	10
136	1 Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 3	7.5	2
135	Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. <i>Journal of Surgical Oncology</i> , <b>2014</b> , 110, 107-14	2.8	129
134	Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 88, 301-5	4	17
133	Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11117-11117	2.2	2
132	Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3509-3509	2.2	8
131	Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3511-3511	2.2	26

130	Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3516-3516	2.2	12
129	Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3517-3517	2.2	14
128	Impact of PI3K aberrations on efficacy of perifosine (P), x-PECT: A phase III randomized study of P plus capecitabine (PC) versus placebo plus capecitabine (C) in refractory metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3606-3606	2.2	1
127	Associations between patient (pt) colorectal cancer (CRC) tumor KRAS and BRAF mutation (mut) status and overall survival (OS).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 473-473	2.2	2
126	A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 488-488	2.2	1
125	Novel Therapies in Development for Metastatic Colorectal Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2014</b> , 7, S2-7		2
124	Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2014</b> , 7, S8-S12		
123	Rechallenge with anti-EGFRBased therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3607-3607	2.2	1
122	Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3619-3619	2.2	
121	Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3633-3633	2.2	
120	Association of prior treatment with anti-EGFR monoclonal antibodies with downregulation of circulating TRAIL and upregulation of EGFR and VEGF family ligands in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 452-452	2.2	
119	Colorectal high-grade neuroendocrine carcinoma: A single institution experience.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 540-540	2.2	
118	Il-8 as an underutilized prognostic factor in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 409-409	2.2	
117	Association between KRAS mutation and lung metastasis in advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 494-494	2.2	
116	Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 450-450	2.2	
115	Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. <i>Cancer</i> , <b>2013</b> , 119, 2778-88	6.4	36
114	CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. <i>Genome Research</i> , <b>2013</b> , 23, 1446-61	9.7	442
113	A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2349-53	10.3	25

112	Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 657-67	12.9	205
111	Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. <i>Hpb</i> , <b>2013</b> , 15, 116-8	3.8	3
110	Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. <i>Cancer</i> , <b>2013</b> , 119, 4231-41	6.4	39
109	Challenges and strategies for identifying biomarkers for colorectal cancer. <i>Colorectal Cancer</i> , <b>2013</b> , 2, 487-489	0.8	1
108	RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. <i>Annals of Surgery</i> , <b>2013</b> , 258, 619-26; discussion 626-7	7.8	251
107	Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 2857-63	6.1	35
106	Use of research biopsies in clinical trials: are risks and benefits adequately discussed?. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 17-22	2.2	210
105	Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. <i>Annals of Surgery</i> , <b>2013</b> , 257, 1079-88	7.8	138
104	Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. <i>PLoS ONE</i> , <b>2013</b> , 8, e65144	3.7	44
103	The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e77117	3.7	84
102	"Right drug for the right patient": hurdles and the path forward in colorectal cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> ,	7.1	6
101	Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3507-3507	2.2	7
100	Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3512-3512	2.2	3
99	Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3612-3612	2.2	2
98	MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 334-334	2.2	1
97	Genomic classifiers (ColoPrint/MSI-Print) predict outcome and chemotherapy benefit in stage II and III colon cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 378-378	2.2	2
96	Increased gene copy number and amplification of FGF2 and FGFR1 in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 402-402	2.2	1
95	BRAF inhibitors in clinical oncology. <i>F1000prime Reports</i> , <b>2013</b> , 5, 11		29

94	Comparison of prognostic genomic predictors in colorectal cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e60778	3.7	17
93	Progression-free survival in metastatic, BRAF-mutated colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 458-458	2.2	
92	Molecular characteristics of complete PTEN loss in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 389-389	2.2	
91	Right Drug for the Right Patient—Hurdles and the Path Forward in Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> , e115-e120	7.1	1
90	Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3530-3530	2.2	
89	A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 1439-45	3.1	89
88	GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. <i>Carcinogenesis</i> , <b>2012</b> , 33, 1327-31	4.6	39
87	Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. <i>Clinical Colorectal Cancer</i> , <b>2012</b> , 11, 297-303	3.8	6
86	Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. <i>Clinical Colorectal Cancer</i> , <b>2012</b> , 11, 191-4	3.8	15
85	Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. <i>Gut</i> , <b>2012</b> , 61, 1291-8	19.2	69
84	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 205	8.5	538
83	A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 820-6	7.5	14
82	Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 779-89	10.1	172
81	Endothelial function, oxidative stress and inflammatory studies in chronic coronary slow flow phenomenon patients. <i>Cardiology</i> , <b>2012</b> , 121, 197-203	1.6	31
80	The promise of patient-derived xenografts: the best laid plans of mice and men. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5160-2	12.9	127
79	KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 1442-3; author reply 1444	8.7	4
78	Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4566-72	2.2	163
77	Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. <i>Annals of Surgery</i> , <b>2012</b> , 256, 642-50	7.8	51



76	BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3528-3528	2.2	11
75	Exploratory analysis of adjuvant chemotherapy effects after preoperative chemoradiotherapy and radical resection for rectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 557-557	2.2	2
74	Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal adenocarcinoma: A phase I trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 544-544	2.2	
73	Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3561-3561	2.2	
72	Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6130-9	12.9	225
71	Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. <i>Clinical Colorectal Cancer</i> , <b>2011</b> , 10, 178-82	3.8	41
70	ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. <i>PLoS ONE</i> , <b>2011</b> , 6, e20636	3.7	211
69	CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. <i>American Journal of Roentgenology</i> , <b>2011</b> , 197, W1060-6	5.4	29
68	Reply to N. Personeni et al. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2734-2735	2.2	
67	Predictive and prognostic markers in colorectal cancer. <i>Current Oncology Reports</i> , <b>2011</b> , 13, 206-15	6.3	39
66	Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. <i>Cancer</i> , <b>2011</b> , 117, 4484-92	6.4	27
65	Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. <i>Cancer</i> , <b>2011</b> , 117, 4623-32	6.4	492
64	Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 2094-103	6.1	29
63	High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1083-90	2.2	293
62	PI-3-Kinase inhibitors in colorectal cancer. <i>Current Cancer Drug Targets</i> , <b>2011</b> , 11, 190-8	2.8	10
61	Association of PTEN loss and local recurrence in stage II-III colon cancer.. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 399-399	2.2	
60	Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 401-401	2.2	1
59	Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. <i>Anticancer Research</i> , <b>2011</b> , 31, 1417-20	2.3	74

58	Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. <i>British Journal of Cancer</i> , <b>2010</b> , 102, 144-50	8.7	93
57	Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 453-9	2.2	383
56	Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2549-55	2.2	151
55	The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. <i>Clinical Colorectal Cancer</i> , <b>2010</b> , 9, 89-94	3.8	58
54	MicroRNAs, ultraconserved genes and colorectal cancers. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2010</b> , 42, 1291-7	5.6	39
53	Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. <i>Acta Oncologica</i> , <b>2010</b> , 49, 474-9	3.2	68
52	Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 1287-94	6.7	60
51	Long-term survival and recurrence outcomes following surgery for distal rectal cancer. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 2863-9	3.1	87
50	Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 2870-6	3.1	186
49	Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?. <i>Journal of the American College of Surgeons</i> , <b>2010</b> , 210, 934-41	4.4	204
48	PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3534-3534	2.2	135
47	Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3592-3592	2.2	2
46	Commentary: practice patterns and potential impact on quality measures for a practicing physician. <i>Journal of Oncology Practice</i> , <b>2009</b> , 5, 233-5	3.1	2
45	Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3677-83	2.2	955
44	Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 302, 2338-44	27.4	373
43	Hidden biases in an observational study of bevacizumab beyond progression. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1732-3; author reply 1733	2.2	13
42	Barriers to Integrating Gene Profiling for Stage II Colon Cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7451-7452	14.52	8
41	Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2598-603	2.2	167

40	Reply to D.J. Gallagher et al. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e20-e21	2.2	1
39	Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. <i>Cell and Tissue Research</i> , <b>2009</b> , 335, 249-59	4.2	68
38	Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 818-23	4	46
37	Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 614-22	3.1	260
36	Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. <i>Cancer Research</i> , <b>2009</b> , 69, 3842-9	10.1	112
35	Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. <i>Clinical Colorectal Cancer</i> , <b>2009</b> , 8, 225-30	3.8	76
34	Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. <i>Journal of Hematology and Oncology</i> , <b>2009</b> , 2, 18	22.4	35
33	Systemic Therapy for Non-operable Colorectal Cancer Metastases <b>2009</b> , 1-8		
32	A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 722-6	8.7	2
31	Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. <i>Clinical Colorectal Cancer</i> , <b>2008</b> , 7, 55-9	3.8	6
30	Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. <i>Clinical Colorectal Cancer</i> , <b>2008</b> , 7, 338-42	3.8	
29	Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. <i>Cancer Investigation</i> , <b>2008</b> , 26, 794-9	2.1	59
28	Perioperative chemotherapy for resectable hepatic metastases. <i>Lancet, The</i> , <b>2008</b> , 371, 963-5	40	62
27	Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2000-5	2.2	15
26	Clinical findings of a palliative care consultation team at a comprehensive cancer center. <i>Journal of Palliative Medicine</i> , <b>2008</b> , 11, 191-7	2.2	44
25	Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5254-60	2.2	153
24	Emerging drugs for colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , <b>2008</b> , 13, 629-42	3.7	9
23	Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5344-51	2.2	458

22	Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. <i>Investigational New Drugs</i> , <b>2008</b> , 26, 445-54	4.3	70
21	Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. <i>Cancer</i> , <b>2008</b> , 112, 2283-8	6.4	43
20	Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. <i>Cancer</i> , <b>2008</b> , 113, 2038-45	6.4	95
19	First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3577-3577	2.2	29
18	The use of 5-fluorouracil and oxaliplatin (FOLFOX) for colorectal cancer is associated with the development of splenomegaly and thrombocytopenia. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4102-4102 <sup>2.2</sup>	2.2	2
17	Targeted Therapy in Colorectal Cancer <b>2008</b> , 101-123		2
16	Novel targets for systemic therapy of colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , <b>2008</b> , 6, 38-40	0.6	
15	Adjuvant chemotherapy for stage II colon cancer. <i>Oncology</i> , <b>2008</b> , 22, 260-70; discussion 270, 273, 275	1.8	18
14	Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. <i>Journal of Gastrointestinal Surgery</i> , <b>2007</b> , 11, 1498-504; discussion 1504-5	3.3	135
13	Src continues aging: current and future clinical directions. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 7232-6	12.9	94
12	Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. <i>European Respiratory Journal</i> , <b>2007</b> , 29, 813-5	13.6	6
11	Presence of survivin-specific cytotoxic T-lymphocytes (CTLs) in pancreatic cancer patients, and specific killing of human pancreatic carcinoma cells in vitro by survivin-specific CTLs. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3070-3070	2.2	1
10	Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4089-4089	2.2	2
9	Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2007</b> , 1, S37-41		11
8	Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3579-3579	2.2	7
7	The establishment of a palliative care consult team in a comprehensive cancer center. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8093-8093	2.2	
6	Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in management. <i>Oncology</i> , <b>2005</b> , 19, 11-7	1.8	3
5	Characteristics and outcomes of dementia residents in an assisted living facility. <i>International Journal of Geriatric Psychiatry</i> , <b>2000</b> , 15, 586-93	3.9	73

4	Characteristics and outcomes of dementia residents in an assisted living facility <b>2000</b> , 15, 586	2
3	RETRIEVAL OF AEROSOL OPTICAL THICKNESS BY MEANS OF THE LEAST-MEDIAN-SQUARES ROBUST ALGORITHM. <i>Journal of Aerosol Science</i> , <b>1999</b> , 30, 805-817	43 6
2	Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract	3
1	Tumor cell total mRNA expression shapes the molecular and clinical phenotype of cancer	2